Hospira (HSP +1.2%) says results from a post-marketing study of the company's European...
Hospira (HSP +1.2%) says results from a post-marketing study of the company's European biosimilar epoetin, Retacrit, met its primary endpoint in the management of chemotherapy-induced anemia in adult patients with solid tumors, lymphomas and myelomas, regardless of chemotherapy cycle..
From other sites
at Nasdaq.com (Wed, 11:30AM)
at Zacks.com (Apr 8, 2015)
at MarketWatch.com (Feb 12, 2015)
at Benzinga.com (Feb 12, 2015)
at MarketWatch.com (Feb 10, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs